Maxim Group on Omeros: Do the Math – It’s a Buy! (OMER)

Omeros Corporation (OMER) is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system. Their most clinically advanced product candidates are derived from proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures.

Maxim Group has initiated coverage of Omeros Corporation, giving it a "Buy" recommendation and a 12-month target price of $23.  

Analyst Jason Kolbert writes,

"Omeros is an unusual combination of specialty pharmaceuticals and biotechnology drug discovery. On the specialty pharma side, we see great value in the ophthalmological surgery program. While we believe in the arthroscopic surgery platform, we are staying on the conservative side and not including positive results in our FCF or EPS models."

Read the full report below. 

Omer initiation

View more documents from DailyDoseEquities.

Rodman & Renshaw Raise Target Price of Omeros Corp (NASDAQ:OMER) to $16/sh

Omeros Corporation (NASDAQ: OMER) is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system. Their most clinically advanced product candidates are derived from their proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Leveraging clinical development experience and expertise in inflammation and the central nervous system, Omeros has built multiple development programs targeting large markets. By combining late-stage PharmacoSurgery  product candidates with this deep and diverse pipeline of preclinical development programs, Omeros creates multiple opportunities for commercial success.

Omeros has released the results from its Phase 3 clinical trials of combination drug OMS302. This large 405-patient study demonstrated that OMS302 successfully maintained pupil dilation compared to placebo in intraocular lens replacement surgeries. It furthermore met its secondary endpoint, reducing post-operative pain in study participants. The success of OMS302 is particularly relevant because,

"A well-dilated pupil is imperative for a safe and successful surgery, as most of lens replacement procedures – in particular cataract surgeries – are performed behind the pupil. If the pupil fails to dilate properly (decreasing the surgeon’s operative field), there is an increased risk of complications. OMS302 not only successfully maintained pupil dilation during surgery, but also decreased pain in the postoperative period compared to placebo. Both outcomes are clinically relevant for surgeons and patients. OMS302 was well tolerated, and the adverse event profile for the drug was similar to placebo."

Due to the results of this study, the Rodman & Renshaw analysts are maintaining their Market Outperform rating and raising their Target Price from $13 to $16/sh.

See the full report below.

Rodman & Renshaw Report on Omeros Corp

View more documents from DailyDoseEquities